For the month ended 31 July 2026, Kaisa Health Group Holdings Limited reported no changes to either its authorised or issued share capital, according to the company’s monthly return filed with Hong Kong Exchanges and Clearing Limited on 4 August 2026.

Authorised share capital remained at 3.20 billion ordinary shares with a par value of HKD 0.0625 each, equivalent to HKD 200.00 million.

Issued share capital was unchanged at 103.63 million ordinary shares, and the company held no treasury shares. Consequently, total issued shares at month-end matched the prior-month balance of 103.63 million.

Kaisa Health confirmed compliance with the Main Board’s minimum public-float threshold of 25%, stating that sufficient shares were held by public investors as at 31 July 2026.

Share-based incentives saw an adjustment rather than new issuance. Following the 1-for-50 share consolidation effective 24 June 2026, the number of outstanding options under the 8 June 2015 scheme was recalibrated from 62.00 million to 1.24 million, with the exercise price correspondingly reset to HKD 9.80 per share. No options were granted, exercised, lapsed or cancelled during July, and no new shares were issued pursuant to option exercises. The new share option scheme approved on 29 June 2026 had no options outstanding or granted during the month.

The company reported no warrants, convertible securities, treasury-share movements or Hong Kong Depositary Receipts during the period.

Overall, Kaisa Health’s capital structure and share count were unchanged in July 2026, with all regulatory confirmations duly filed by Company Secretary Yu Kwok Leung.